Trading Signals: VBIV Stock Price Prediction and Forecast (Thu. May. 4, 2006 - Fri. Jul. 24, 2020)(VBI Vaccines Inc)
| VBIV latest price $30.0000 (-3.69%) ($29.4000 - $31.5500) on Mon. Sep. 27, 2010. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 7.02% (three month average) | | RSI | 59 | | Latest Price | $30.0000(-3.69%) | | Stocks Behave Similarly | Similar Stock List | | Daily Trend | VBIV declines -3.7% a day on average for past five trading days. | | Market Behavior | Normal for large cap. Normal for small cap. | | Correlated ETFs | Broad market will support VBIV advance at 0% a week (0% probability)
GLD(19%) EEM(12%) FXI(12%) OIH(12%) VWO(12%) | | Factors Impacting VBIV price | VBIV will decline at least -3.51% in a week (0% probabilities).
TLT(-7%) TIP(-0%) SHY(1%) LQD(2%) XLU(5%) | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -3.51% (StdDev 7.02%) | | Hourly BBV | 0 () | | Intraday Trend | -4.1% | | | | | |
|
| Resistance Level | $32.1 | | 5 Day Moving Average | $31.93(-6.04%) | | 10 Day Moving Average | $33.78(-11.19%) | | 20 Day Moving Average | $32.1(-6.54%) | | To recent high | -17.9% | | To recent low | 86.3% | | Market Cap | $6.919b | | | | | | |
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.VBI's COVID-19 vaccine candidate, VBI-2901, is noteworthy because it could potentially also confer immunity to other coronaviruses which cause diseases like MERS (Middle Eastern Respiratory Syndrome). More importantly, VBI appears to be facing a bottleneck either in its preclinical research or its vaccine manufacturing capabilities. VBI doesn't expect to have the necessary clinical study materials assembled for its COVID-19 vaccine trial before the fourth quarter, meaning that it's roughly a quarter behind Vaxart in the development process. |